Qt Imaging Holdings, Inc. · NASDAQ:QTI
Qt Imaging — Investor Presentation (February 2024)
34 slides from Qt Imaging's investor presentation, February 2024
Slide 1: Ultralow Frequency Transmitted Sound Imaging
Ultralow Frequency Transmitted Sound Imaging INVESTOR PRESENTATION February 2024
Slide 2: Disclaimer
Disclaimer ABOUT THIS PRESENTATION This investor presentation (this “Presentation”) is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to the proposed business combination (the “Proposed Business Combination”) be
Slide 3: QT Imaging Has the Potential to Transform Medical Imaging
QT Imaging Has the Potential to Transform Medical Imaging • QTI is a medical device company with imaging technology that has the potential to transform the industry • QTI Scanner is the only imaging device to receive FDA clearance for use as a transmission ultrasonic imaging system of a patient’s br
Slide 4: Introduction to the QT Imaging Management Team
Introduction to the QT Imaging Management Team John Klock, MD CEO & CHIEF Dr. Klock co-founded QT Imaging in 2011 and spearheaded the development and commercialization of the QT MEDICAL Scanner. Prior to QTI, he was involved in the founding of multiple disruptive medical companies, including BioMari
Slide 5: Our Mission
Our Mission • Develop a safe, more accurate comprehensive imaging system, while increasing the speed and lowering the cost of medical imaging • Develop an FDA-cleared, innovative imaging system capable of detecting masses in dense breasts • Develop a safe, full-body imaging technology that can be at
Slide 6: Executive Summary
Executive Summary • Low-cost, comprehensive, no radiation medical imaging solution yielding sub-millimeter, high-definition, image resolution: application in areas such as breast • infant body • orthopedics • Commercial stage, FDA-cleared(1) breast scanner for dense breast imaging, with better sensi
Slide 7: QTI's Technology Has the Opportunity to Transform Several Large Markets
QTI’s Technology Has the Opportunity to Transform Several Large Markets 2022 GLOBAL MEDICAL IMAGING MARKET SIZE: $29B(1) Current Market Future Markets – Body Scanner Platform Development IMAGE-GUIDED PROCEDURES: BREAST: $5B MARKET(2) ORTHO: $9B MARKET(3) INFANT: $8B MARKET (4) $5B MARKET(5) • FDA ap
Slide 8: Investment Highlights
Investment Highlights Cutting-edge imaging technology with multiple potential applications creates a tremendous opportunity to transform the imaging market Industry-Transforming NXC Imaging Agreement Imaging Technology to Drive Accelerated Platform Recognized by Commercial Roll-out Industry Incumben
Slide 9: Agreement Signed with NXC Imaging (A Subsidiary of Canon Medical Systems)
Agreement Signed with NXC Imaging (A Subsidiary of Canon Medical Systems) • Sales Agent Agreement signed with NXC Imaging marks a major milestone for QT Imaging • Accessing NXC Imaging's distribution channel in the US and the US territories, this agreement provides potential to accelerate the commer
Slide 10: Technology Overview
.@) imaging TECHNOLOGY OVERVIEW
Slide 11: Current Ultrasound Technologies Have Major Deficiencies
Current Ultrasound Technologies Have Major Deficiencies Shortfalls of Current, Rival Systems • Reflection and compounding artifacts • No valid true “transmission” mode – use “shear wave” (low resolution) data • Data yielded is compounded 2D – not true “3D” • “Speed” photos provide compromised resolu
Slide 12: Why Does QTI Volography Have 40x the Resolution of The Best MRI?
Why Does QTI Volography Have 40x the Resolution of The Best MRI? More Data planar MRI QTI Volography (3D volumetric UT) 2mm gap – no 20mm data collected overlapping Receiver Array detectors Receiver Array QT duplication of data means: • Higher Resolution 22 million voxels • Higher Detection • Higher
Slide 13: Transmission Ultrasound Capabilities
Transmission Ultrasound Capabilities Technical • Resolution of 50-100 microns compared to…..for MRI • Contrast to noise ratio of 23:1 at 100 microns • Artifact-free because of speed correction of reflection vologram • Volumetric data acquisition, not stacked 2D slices • Volumetric accuracy of + 0.2%
Slide 14: Resolution and Detectability: MRI vs QTI Volography (3D UT)
Resolution and Detectability: MRI vs QTI Volography (3D UT) MRI QTI Volography ALVEOLI ~40x Volography (3D UT) with reflection mode MRI image of a piglet lung resolution of 3T MRI • Resolution is almost isotropic MRI resolution depends on acquisition • Sub-mm resolution time, B1 inhomogeneity, etc.
Slide 15: Breast Health
.@) imaging BREAST HEALTH
Slide 16: QT Imaging's FDA-cleared Solution for Dense Breasts
QT Imaging’s FDA-cleared Solution for Dense Breasts MANY WOMEN HAVE DENSE BREASTS, WHICH THE FDA HAS RECOGNIZED THE IMPORTANCE OF MAMMOGRAMS ARE INEFFICIENT IN SCREENING BREAST DENSITY IN BREAST CANCER SCREENING FOR CANCER 50% 50% 50% of women between the ages of 40- (3) 74 in the US have dense brea
Slide 17: Dense Breast Imaging Study Confirmed DBT = 40% False-Negatives
CLINICAL TRIALS: Dense Breast Imaging Study Confirmed DBT = 40% False-Negatives Approximately 50% of women between the ages of 40-74 in the US have dense breasts(1), with traditional mammography missing 35.6-52.2% of breast cancers in dense breast tissue(2) making QT Scanner the only system effectiv
Slide 18: Other Ultrasound Products Use B-mode Imaging for Dense Breast Screening
Other Ultrasound Products Use B-mode Imaging for Dense Breast Screening INVENIA ABUS ACUSON S2000 ABVS AWBUS SOFIA 3D DELPHINUS SOFTVUE QT BREAST SCANNER DESIGN TYPE Articulating Arm Articulating Arm Articulating Arm Rotating Armature Water Bath Water Bath Guided Handheld OUTPUT Stacked 2D Stacked 2
Slide 19: The Current Breast Imaging Paradigm Leads to Unnecessary Concern and Costs
The Current Breast Imaging Paradigm Leads to Unnecessary Concern and Costs SCREENING COMPLIANCE IS LOW FOR EVERY 1,000 SCREENING MAMMOGRAMS: 35% of women aged 40–70 do 35% not get screened.(1) FALSE-NEGATIVE RATES 98% OF 65% ~15% false-negative rates RECALLS ARE with mammography AVOIDABLE Do not fol
Slide 20: Current and Future Uses of QT Breast Scanner
Current and Future Uses of QT Breast Scanner The QT Breast Scanner has been granted FDA clearances that allow for meaningful clinical use, with potential for a future roadmap to provide a replacement to screening mammography, a transformational milestone that would significantly expand the market op
Slide 21: QTI Offers Potential Capabilities for Screening, Diagnosis, and Monitoring
QTI Offers Potential Capabilities for Screening, Diagnosis, and Monitoring SUPPLEMENTAL SCREENING • Complementary screening DIAGNOSIS (Approved) − Dense Breasts • Quantification of fibroglandular − Intermediate to high-risk women volume (Approved) MONITORING − Implants • AI-enabled diagnostics • Abi
Slide 22: The QT Scanner Delivers a Better Experience for Patients than Traditional Systems
The QT Scanner Delivers a Better Experience for Patients than Traditional Systems QT IMAGING HANDHELD ULTRASOUND MRI MAMMOGRAPHY Image Quality Safety(1) Speed Cost Efficiency Patient Experience …OVER HHUS …OVER MRI ...OVER MAMMOGRAPHY • Superior image quality • High resolution and • Improved image q
Slide 23: QTI's Breast Acoustic CT Technology
QTI’s Breast Acoustic CTTM Technology Technical Performance QT ScanTM • Very high clinical perspicuity • Has higher sensitivity for lesions and higher specificity and fewer call-backs than screening mammography • 10x sensitivity of 3T MRI • Over 10% improved AUC-ROC in two large clinical trials • >5
Slide 24: QTI Clinical Trials Provide Compelling Results for Adoption and Approvals
QTI Clinical Trials Provide Compelling Results for Adoption and Approvals Clinical Trials Implication of Results or Preliminary Results • Visual Grading Assessment of Quantitative Transmission Ultrasound Compared to Digital X-ray Mammography and Hand-held Ultrasound QT can see more anatomy than mamm
Slide 25: Two Blinded Randomized Trials Completed and Published
CLINICAL TRIALS: Two Blinded Randomized Trials Completed and Published QT PERFORMANCE RELATIVE TO FFDM AND DBT IN MASS DETECTION STUDY #1 FFDM STUDY #2 (Comparison to Digital Breast Tomosynthesis) VS In recent studies, QT outperformed today’s gold standard (Digital Breast Tomosynthesis) (1) Study #1
Slide 26: Clinical Adoption
.@) imaging CLINICAL ADOPTION
Slide 27: Key Milestones Have Been Achieved, with Additional Catalysts to Drive Commercial Adoption
Key Milestones Have Been Achieved, with Additional Catalysts to Drive Commercial Adoption and Increased Market Share BREAST SCANNER 18 MONTHS Key Milestones Achieved for Commercial Adoption P Four placements in North America P Three placements internationally ̶ Generate and publish clinical data KEY
Slide 28: Pricing Structures Allow Providers Flexibility in Using the QT Scanner
Pricing Structures Allow Providers Flexibility in Using the QT Scanner INITIAL TARGET MARKETS Academic Medical Centers PRICING MODEL* 1.Traditional Upfront Purchase Community Cancer Centers 2.MSaaS (Medical Scan as a Service)/Per Click Model Private 3. Turnkey Model (includes scan interpretation) Pr
Slide 29: Reimbursement Will Be Driven by the Value and Savings Provided to Patients
Reimbursement Will Be Driven by the Value and Savings Provided to Patients CURRENT FUTURE • Existing CPT codes, non-specific to QTI • CPT code specific to QT Scanner® technology: − Higher reimbursements capture full value of − Unilateral or Bilateral breast ultrasound unique advantages that QT Scans
Slide 30: Open Angle Scanner
.@) imaging OPEN ANGLE SCANNER
Slide 31: Developing an Open Angle Scanner Will Expand the Technology to New Markets
Developing an Open Angle Scanner Will Expand the Technology to New Markets DEVELOPMENT OF THE OPEN ANGLE SCANNER … PROVIDING SIGNIFICANT POTENTIAL TO ACCESS IS UNDERWAY… NEW MARKETS AND APPLICATIONS • QTI has successfully completed feasibility studies for partial • The Open Angle Scanner uses an ope
Slide 32: The Infrastructure is in Place to Allow for the Rollout of the Next Generation Scanner
The Infrastructure is in Place to Allow for the Rollout of the Next Generation Scanner NEXT GENERATION OPEN ANGLE SCANNER 18 MONTHS Key Infrastructure in Place for Development ü Underlying ultra-low frequency sound emitting technology ü Initial Proof of Concept ü Commencement of prototype design and
Slide 33: Open Angle Scanner Development Pathway and Corresponding Catalysts
Open Angle Scanner Development Pathway and Corresponding Catalysts Open Angle Hardware Proof of Prototype Design & Build Development Concept (First Clinical Trials) 510(k) Ortho Software Software Development Submitted w/Hardware Rollout Development (First Clinical Trials) (FDA Clearance) Infant Soft
Slide 34: Thank You!
.@) imaging THANK YOU!
QT Imaging Holdings — Investor Presentation (February 2024) on 6ix